FDA — authorised 31 March 1982
- Application: NDA018514
- Marketing authorisation holder: BAUSCH
- Local brand name: LOCOID
- Indication: CREAM — TOPICAL
- Status: approved
🇺🇸 hydrocortisone 17-butyrate 0.1% Cream preparation in United States
FDA authorised hydrocortisone 17-butyrate 0.1% Cream preparation on 31 March 1982
Marketing authorisations
FDA — authorised 29 October 1982
- Application: NDA018652
- Marketing authorisation holder: PRECISION DERMAT
- Local brand name: LOCOID
- Indication: OINTMENT — TOPICAL
- Status: approved
FDA — authorised 18 May 2007
- Application: NDA022076
- Marketing authorisation holder: BAUSCH
- Local brand name: LOCOID
- Indication: LOTION — TOPICAL
- Status: approved
FDA
- Status: approved
FDA
- Application: NDA018795
- Marketing authorisation holder: YAMANOUCHI
- Local brand name: LOCOID
- Indication: CREAM — TOPICAL
- Status: approved
FDA
- Application: NDA019819
- Marketing authorisation holder: YAMANOUCHI
- Local brand name: LOCOID
- Indication: SOLUTION — TOPICAL
- Status: approved
hydrocortisone 17-butyrate 0.1% Cream preparation in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is hydrocortisone 17-butyrate 0.1% Cream preparation approved in United States?
Yes. FDA authorised it on 31 March 1982; FDA authorised it on 29 October 1982; FDA authorised it on 18 May 2007.
Who is the marketing authorisation holder for hydrocortisone 17-butyrate 0.1% Cream preparation in United States?
BAUSCH holds the US marketing authorisation.